These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 23757505)

  • 1. Pluripotent stem cells in translation: a Food and Drug Administration-National Institutes of Health collaboration.
    Kleitman N; Rao MS; Owens DF
    Stem Cells Transl Med; 2013 Jul; 2(7):483-7. PubMed ID: 23757505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Law, ethics, religion, and clinical translation in the 21st century--a discussion with Derek Hei. Interview by Majlinda Lako, Alan O. Trounson, Susan Rainey Daher.
    Hei D
    Stem Cells; 2010 Mar; 28(3):387-9. PubMed ID: 20166151
    [No Abstract]   [Full Text] [Related]  

  • 3. Hurdles to clinical translation of human induced pluripotent stem cells.
    Neofytou E; O'Brien CG; Couture LA; Wu JC
    J Clin Invest; 2015 Jul; 125(7):2551-7. PubMed ID: 26132109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Who's in favor of translational cell therapy for stroke: STEPS forward please?
    Chopp M; Steinberg GK; Kondziolka D; Lu M; Bliss TM; Li Y; Hess DC; Borlongan CV
    Cell Transplant; 2009; 18(7):691-3. PubMed ID: 19796499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory considerations for pluripotent stem cell therapies.
    Carpenter MK
    Prog Brain Res; 2017; 230():151-163. PubMed ID: 28552227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hope for regenerative treatments: toward safe transplantation of human pluripotent stem-cell-based therapies.
    Kimbrel EA; Lanza R
    Regen Med; 2015; 10(2):99-102. PubMed ID: 25835474
    [No Abstract]   [Full Text] [Related]  

  • 7. A review of the National Institutes of Health's "Guidelines for Research Using Human Pluripotent Stem Cells".
    Tarne E;
    Issues Law Med; 2002; 17(3):293-307. PubMed ID: 11930959
    [No Abstract]   [Full Text] [Related]  

  • 8. 2005 Donor Eligibility Requirements: Unintended Consequences for Stem Cell Development.
    Couture LA; Carpenter MK
    Stem Cells Transl Med; 2015 Oct; 4(10):1097-100. PubMed ID: 26285658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Key anticipated regulatory issues for clinical use of human induced pluripotent stem cells.
    Knoepfler PS
    Regen Med; 2012 Sep; 7(5):713-20. PubMed ID: 22830621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.
    Lieberman R; Nelson WG; Sakr WA; Meyskens FL; Klein EA; Wilding G; Partin AW; Lee JJ; Lippman SM
    Urology; 2001 Apr; 57(4 Suppl 1):4-27. PubMed ID: 11295590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concise review: making and using clinically compliant pluripotent stem cell lines.
    Carpenter MK; Rao MS
    Stem Cells Transl Med; 2015 Apr; 4(4):381-8. PubMed ID: 25722426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene therapy for rare diseases: summary of a National Institutes of Health workshop, September 13, 2012.
    O'Reilly M; Kohn DB; Bartlett J; Benson J; Brooks PJ; Byrne BJ; Camozzi C; Cornetta K; Crystal RG; Fong Y; Gargiulo L; Gopal-Srivastava R; High KA; Jacobson SG; Jambou RC; Montgomery M; Rosenthal E; Samulski RJ; Skarlatos SI; Sorrentino B; Wilson JM; Xie Y; Corrigan-Curay J
    Hum Gene Ther; 2013 Apr; 24(4):355-62. PubMed ID: 23517518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Draft National Institutes of Health guidelines for research involving human pluripotent stem cells (December 1999).
    National Institutes of Health
    Cloning; 1999-2000; 1(4):225-31. PubMed ID: 16218823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell therapy for stroke: remaining issues to address before embarking on clinical trials.
    Borlongan CV
    Stroke; 2009 Mar; 40(3 Suppl):S146-8. PubMed ID: 19064801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expand and regularize federal funding for human pluripotent stem cell research.
    Owen-Smith J; Scott CT; McCormick JB
    J Policy Anal Manage; 2012; 31(3):714-22. PubMed ID: 22764380
    [No Abstract]   [Full Text] [Related]  

  • 17. Translating stem cell studies to the clinic for CNS repair: current state of the art and the need for a Rosetta stone.
    Aboody K; Capela A; Niazi N; Stern JH; Temple S
    Neuron; 2011 May; 70(4):597-613. PubMed ID: 21609819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stem cells: current challenges and future promise.
    Battey JF
    Dev Dyn; 2007 Dec; 236(12):3193-8. PubMed ID: 17584855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maternal immunization efforts of the National Institutes of Health.
    Rubin FA; Koso-Thomas M; Isaacs MB; Piper J; Read J; Nesin M
    Vaccine; 2015 Nov; 33(47):6380-7. PubMed ID: 26458798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From bench to FDA to bedside: US regulatory trends for new stem cell therapies.
    Knoepfler PS
    Adv Drug Deliv Rev; 2015 Mar; 82-83():192-6. PubMed ID: 25489841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.